journal article·2023-12Open access

Tumor Environment Regression Therapy Implemented by Switchable Prune‐to‐Essence Nanoplatform Unleashed Systemic Immune Responses

Xianzhou Huang, Lu Li, Chunqing Ou, Meiling Shen, Xinchao Li, Miaomiao Zhang, Rui Wu, Xiaorong Kou, Ling Gao, Furong Liu, Rui Luo, Qinjie Wu, Changyang Gong

Advanced Science· Volume 10· Issue 35

Abstract

Abstract Coevolution of tumor cells and surrounding stroma results in protective protumoral environment, in which abundant vessel, stiff structure and immunosuppression promote each other, cooperatively incurring deterioration and treatment compromise. Reversing suchenvironment may transform tumors from treatment‐resistant to treatment‐vulnerable. However, effective reversion requires synergistic comprehensive regression of such environment under precise control. Here, the first attempt to collaboratively retrograde coevolutionary tumor environment to pre‐oncogenesis status, defined as tumor environment regression therapy, is made for vigorous immune response eruption by a switchable prune‐to‐essence nanoplatform (Pres) with simplified composition and fabrication process. Through magnetic targeting and multimodal imaging of Pres, tumor environment regression therapy is guided, optimized and accomplished in a trinity way: Antiangiogenesis is executed to rarefy vessels to impede tumor progression. By seizing the time, cancer associated fibroblasts are eliminated to diminish collagen and loosen the stiff structure for deep penetration of Pres, which alternately functioned in deeper tumors, forming a positive feedback loop. Through this loop, immune cell infiltration, immunosuppression mitigation and immunogenic cells death induction are all fulfilled and further escalated in the regressed environment. These transformations consequently unleashed systemic immune responses and generated immune memory against carcinoma. This study provides new insights intotreatment of solid tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biotherapy Cancer center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu 610041 China

Department of Medical Oncology Cancer Center West China Hospital Sichuan University Chengdu 610041 China

Funding

National Natural Science Foundation of China · West China Hospital, Sichuan University · Postdoctoral Research Foundation of China

References (51)

Show source-provided references
1. 10.1038/s41586-020-03147-x10.1038/s41586-020-03147-x ↗
2. 10.1158/2159-8290.CD-22-019610.1158/2159-8290.CD-22-0196 ↗
3. 10.1038/s41586-020-2977-210.1038/s41586-020-2977-2 ↗
4. 10.1038/s41467-021-22804-x10.1038/s41467-021-22804-x ↗
5. 10.1038/s41598-021-03134-w10.1038/s41598-021-03134-w ↗
6. 10.1038/s41563-020-00849-510.1038/s41563-020-00849-5 ↗
7. 10.1038/s41563-019-0377-510.1038/s41563-019-0377-5 ↗
8. 10.1038/nm.408210.1038/nm.4082 ↗
9. 10.1039/c5ib00040h10.1039/c5ib00040h ↗
10. 10.1016/j.ajpath.2010.11.07610.1016/j.ajpath.2010.11.076 ↗
11. 10.15252/embr.20143924610.15252/embr.201439246 ↗
12. 10.1016/j.trecan.2022.02.00710.1016/j.trecan.2022.02.007 ↗
13. 10.1016/j.addr.2015.07.00710.1016/j.addr.2015.07.007 ↗
14. 10.1021/acsnano.6b0277610.1021/acsnano.6b02776 ↗
15. 10.1007/s10555-018-9768-310.1007/s10555-018-9768-3 ↗
16. 10.1038/s41573-018-0004-110.1038/s41573-018-0004-1 ↗
17. 10.1016/j.ccell.2014.10.00610.1016/j.ccell.2014.10.006 ↗
18. 10.1126/sciimmunol.abm638810.1126/sciimmunol.abm6388 ↗
19. 10.1371/journal.pgen.100524910.1371/journal.pgen.1005249 ↗
20. 10.1186/s13058-019-1194-010.1186/s13058-019-1194-0 ↗
21. 10.1126/sciadv.abd785110.1126/sciadv.abd7851 ↗
22. 10.1200/JCO.2022.40.16_suppl.e1605810.1200/JCO.2022.40.16_suppl.e16058 ↗
23. 10.1038/nature1014410.1038/nature10144 ↗
24. 10.7150/thno.2482110.7150/thno.24821 ↗
25. 10.1039/C9NR09610H10.1039/C9NR09610H ↗
26. 10.1088/1361-6528/ab94dc10.1088/1361-6528/ab94dc ↗
27. 10.1016/j.cell.2020.12.03110.1016/j.cell.2020.12.031 ↗
28. 10.1021/acsnano.0c0772110.1021/acsnano.0c07721 ↗
29. 10.1021/acsnano.8b0714110.1021/acsnano.8b07141 ↗
30. 10.1016/j.biomaterials.2019.11951510.1016/j.biomaterials.2019.119515 ↗
31. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
32. 10.1016/j.tox.2018.07.00910.1016/j.tox.2018.07.009 ↗
33. 10.1016/j.tox.2019.15228110.1016/j.tox.2019.152281 ↗
34. 10.1002/adma.20120468310.1002/adma.201204683 ↗
35. 10.1002/anie.20180566410.1002/anie.201805664 ↗
36. 10.1021/acs.nanolett.9b0063010.1021/acs.nanolett.9b00630 ↗
37. 10.1021/acs.nanolett.9b0120210.1021/acs.nanolett.9b01202 ↗
38. 10.1002/adma.20190438510.1002/adma.201904385 ↗
39. 10.1002/adma.20150570010.1002/adma.201505700 ↗
40. 10.1039/C9MH01197H10.1039/C9MH01197H ↗
41. 10.1021/acsnano.1c1061810.1021/acsnano.1c10618 ↗
42. 10.1007/s11426-018-9392-610.1007/s11426-018-9392-6 ↗
43. 10.1016/j.jconrel.2016.11.01310.1016/j.jconrel.2016.11.013 ↗
44. 10.1002/adfm.20200701710.1002/adfm.202007017 ↗
45. 10.1016/j.cclet.2021.11.04810.1016/j.cclet.2021.11.048 ↗
46. 10.3389/fimmu.2020.0202610.3389/fimmu.2020.02026 ↗
47. 10.1038/s41551-019-0375-610.1038/s41551-019-0375-6 ↗
48. 10.1126/scitranslmed.abl364910.1126/scitranslmed.abl3649 ↗
49. 10.1021/acsnano.8b0145610.1021/acsnano.8b01456 ↗
50. 10.1021/nn203293t10.1021/nn203293t ↗
51. 10.1002/smll.20100110910.1002/smll.201001109 ↗